ZA200703696B - Site-directed modification of FVIII - Google Patents

Site-directed modification of FVIII

Info

Publication number
ZA200703696B
ZA200703696B ZA200703696A ZA200703696A ZA200703696B ZA 200703696 B ZA200703696 B ZA 200703696B ZA 200703696 A ZA200703696 A ZA 200703696A ZA 200703696 A ZA200703696 A ZA 200703696A ZA 200703696 B ZA200703696 B ZA 200703696B
Authority
ZA
South Africa
Prior art keywords
fviii
site
directed modification
modification
directed
Prior art date
Application number
ZA200703696A
Other languages
English (en)
Inventor
Clark Q Pan
John E Murphy
Mei Baison
Jonathan S Strauss
Tjandra Hendri
Chen Jianmin
Barnett Thomas
Tang Liang
Wang Deqian
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36337298&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200703696(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Publication of ZA200703696B publication Critical patent/ZA200703696B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/08—Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Materials For Medical Uses (AREA)
  • Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
ZA200703696A 2004-11-12 2007-05-08 Site-directed modification of FVIII ZA200703696B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US62727704P 2004-11-12 2004-11-12

Publications (1)

Publication Number Publication Date
ZA200703696B true ZA200703696B (en) 2008-08-27

Family

ID=36337298

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200703696A ZA200703696B (en) 2004-11-12 2007-05-08 Site-directed modification of FVIII

Country Status (32)

Country Link
US (4) US7632921B2 (fr)
EP (9) EP3243834A1 (fr)
JP (5) JP2008524117A (fr)
KR (7) KR20180110192A (fr)
CN (6) CN103214569B (fr)
AU (1) AU2005304622B2 (fr)
BE (1) BE2019C523I2 (fr)
BR (2) BRPI0517795B8 (fr)
CA (1) CA2586379C (fr)
CY (3) CY1119292T1 (fr)
DK (3) DK2363414T3 (fr)
ES (4) ES2930159T3 (fr)
FR (1) FR19C1031I2 (fr)
HN (1) HN2007015683A (fr)
HR (2) HRP20070268B1 (fr)
HU (5) HUE033776T2 (fr)
IL (3) IL182903A (fr)
LT (5) LT1824988T (fr)
LU (1) LUC00118I2 (fr)
MA (1) MA29663B1 (fr)
MX (3) MX350293B (fr)
NL (1) NL300989I2 (fr)
NO (3) NO20210454A1 (fr)
NZ (1) NZ555032A (fr)
PH (2) PH12014500352B1 (fr)
PL (3) PL2363414T3 (fr)
PT (4) PT2363414T (fr)
RU (1) RU2423380C2 (fr)
SI (4) SI2363414T1 (fr)
UA (1) UA95225C2 (fr)
WO (1) WO2006053299A2 (fr)
ZA (1) ZA200703696B (fr)

Families Citing this family (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1615945T3 (pl) 2003-04-09 2012-03-30 Ratiopharm Gmbh Sposoby glikopegylacji i białka/peptydy wytwarzane tymi sposobami
US9005625B2 (en) 2003-07-25 2015-04-14 Novo Nordisk A/S Antibody toxin conjugates
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
CA2571292C (fr) * 2004-06-30 2013-05-21 Nektar Therapeutics Al, Corporation Conjugues polymere-fraction facteur ix
US20080300173A1 (en) 2004-07-13 2008-12-04 Defrees Shawn Branched Peg Remodeling and Glycosylation of Glucagon-Like Peptides-1 [Glp-1]
WO2006050247A2 (fr) 2004-10-29 2006-05-11 Neose Technologies, Inc. Remodelage et glycopegylation du facteur de croissance des fibroblastes (fgf)
PT2363414T (pt) 2004-11-12 2022-08-04 Bayer Healthcare Llc Modificação de fviii direcionada a sítio
US9029331B2 (en) 2005-01-10 2015-05-12 Novo Nordisk A/S Glycopegylated granulocyte colony stimulating factor
WO2006121569A2 (fr) 2005-04-08 2006-11-16 Neose Technologies, Inc. Compositions et methodes utilisees pour la preparation de mutants par glycosylation de l'hormone de croissance humaine resistant a la protease
ES2553160T3 (es) 2005-06-17 2015-12-04 Novo Nordisk Health Care Ag Reducción y derivatización selectivas de proteínas Factor VII transformadas por ingeniería que comprenden al menos una cisteína no nativa
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
WO2007056191A2 (fr) 2005-11-03 2007-05-18 Neose Technologies, Inc. Purification de sucre de nucleotide en utilisant des membranes
KR20090013816A (ko) * 2006-05-24 2009-02-05 노보 노르디스크 헬스 케어 악티엔게젤샤프트 연장된 생체내 반감기를 갖는 인자 ⅸ 유사체
EP2049144B8 (fr) 2006-07-21 2015-02-18 ratiopharm GmbH Glycosylation de peptides par l'intermédiaire de séquences de glycosylation à liaison o
EP2054521A4 (fr) 2006-10-03 2012-12-19 Novo Nordisk As Méthodes de purification de conjugués de polypeptides
PT2101821E (pt) 2006-12-15 2014-10-03 Baxter Int Fator conjugado viia-ácido (poli)siálico com prolongamento do tempo de meia vida in vivo
HRP20130382T1 (hr) 2007-04-03 2013-05-31 Biogenerix Ag Postupci lijeäśenja pomoä†u glikopegiliranog g-csf
CA2690611C (fr) 2007-06-12 2015-12-08 Novo Nordisk A/S Procede ameliore pour la production de sucres de nucleotide
KR20100095441A (ko) * 2007-11-09 2010-08-30 백스터 인터내셔널 인코포레이티드 변형된 재조합 인자 ⅷ 및 폰 빌레브란트 인자 및 사용 방법
PL2257311T3 (pl) * 2008-02-27 2014-09-30 Novo Nordisk As Koniugaty cząsteczek czynnika VIII
CN102112144A (zh) * 2008-05-16 2011-06-29 拜耳医药保健有限公司 靶向性凝固因子及其使用方法
EP2297330A4 (fr) * 2008-06-04 2012-03-14 Bayer Healthcare Llc Mutéines du facteur viii pour le traitement de la maladie de von willebrand
PL2291523T3 (pl) 2008-06-24 2015-05-29 Csl Behring Gmbh Czynnik VIII, czynnik von Willebranda lub ich kompleksy o wydłużonym okresie półtrwania in vivo
WO2010019263A2 (fr) * 2008-08-15 2010-02-18 Genzyme Corporation Produits de construction de flt soluble pour traiter des cancers
US20100099616A1 (en) * 2008-10-17 2010-04-22 Baxter International Inc. Modified blood factors comprising a low degree of water soluble polymer
KR20110093775A (ko) * 2008-11-03 2011-08-18 바이엘 헬스케어 엘엘씨 혈우병 치료 방법
EP2368124A4 (fr) * 2008-11-24 2012-09-19 Bayer Healthcare Llc Procédé de détermination d'activité de facteur de coagulation sanguine pégylé dans un essai de temps de thromboplastine partielle activée à base de silice
US20120121613A1 (en) * 2009-01-19 2012-05-17 Bayer Healthcare Llc Protein conjugate having an endopeptidase- cleavable bioprotective moiety
ES2610356T3 (es) 2009-02-03 2017-04-27 Amunix Operating Inc. Polipéptidos recombinantes extendidos y composiciones que comprenden los mismos
ES2401965T3 (es) * 2009-02-19 2013-04-25 Novo Nordisk A/S Modificación de Factor VIII
MX2011009803A (es) * 2009-03-20 2011-09-30 Hanmi Holdings Co Ltd Metodo para preparar un polipeptido conjugado fisiologicamente activo en un sitio especifico.
JP5739865B2 (ja) * 2009-03-24 2015-06-24 バイエル・ヘルスケア・エルエルシー 第ｖｉｉｉ因子変異体および使用の方法
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
JP5909755B2 (ja) 2009-07-27 2016-04-27 リポクセン テクノロジーズ リミテッド 非血液凝固タンパク質の糖ポリシアル酸化
ES2597954T3 (es) 2009-07-27 2017-01-24 Baxalta GmbH Conjugados de proteína de la coagulación sanguínea
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
EP3093029A1 (fr) 2009-07-27 2016-11-16 Baxalta GmbH Conjugués de protéines de coagulation sanguine
CA2771999A1 (fr) 2009-08-24 2011-03-10 Amunix Operating Inc. Compositions de facteurs de coagulation vii et procedes de preparation et d'utilisation de celles-ci
SI2506868T1 (en) 2009-12-06 2018-04-30 Bioverativ Therapeutics Inc. HYPER AND HYBRID POLYPETTIDES FACTOR VIII-FC AND METHODS FOR THEIR USE
WO2011075185A1 (fr) 2009-12-18 2011-06-23 Oligasis Conjugués de polymère de phosphorylcholine à médicament ciblé
EP2536753B1 (fr) 2010-02-16 2017-12-20 Novo Nordisk A/S Molécules de facteur VIII avec liaison VWF réduite
PT2536399T (pt) * 2010-02-21 2020-02-06 Bayer Healthcare Llc Método para ativação e conjugação de biomoléculas
BR112012026118B1 (pt) 2010-04-15 2021-01-05 Oligasis polímeros de alto peso molecular contendo zwitterion
GB201007356D0 (en) 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIIa
GB201007357D0 (en) * 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIII
EP3508573A1 (fr) * 2010-07-09 2019-07-10 Bioverativ Therapeutics Inc. Systèmes de traitement de facteur viii et procédés associés
DK2635297T3 (da) 2010-11-05 2019-05-06 Baxalta GmbH En ny variant af antihæmofil faktor viii, der har en øget specifik aktivitet
CA2821945A1 (fr) * 2010-12-16 2012-06-21 Novo Nordisk A/S Solution aqueuse de facteur viii
BR112013015898A2 (pt) 2010-12-22 2018-06-26 Baxter International Inc. derivado de ácido graxo solúvel em água, e, métodos para preparar um derivado de ácido graxo e uma proteína terapêutica conjugada.
JP2014520094A (ja) * 2011-05-27 2014-08-21 バクスター・インターナショナル・インコーポレイテッド 増加した半減期を有する治療用タンパク質およびそれを調製する方法
US9486507B2 (en) 2011-06-10 2016-11-08 Biogen Ma Inc. Pro-coagulant compounds and methods of use thereof
RU2014103288A (ru) 2011-07-01 2015-08-10 Байер Интеллектчуал Проперти Гмбх Слитые полипептиды релаксина и их применение
PT3513804T (pt) 2011-07-08 2022-06-02 Bioverativ Therapeutics Inc Polipéptidos fator viii híbridos e quiméricos, e métodos de utilização dos mesmos
AU2012311484B2 (en) 2011-09-23 2017-04-13 Novo Nordisk A/S Novel glucagon analogues
KR20130049671A (ko) * 2011-11-04 2013-05-14 한미사이언스 주식회사 생리활성 폴리펩타이드 결합체 제조 방법
EP2822577B1 (fr) * 2012-02-15 2019-02-06 Bioverativ Therapeutics Inc. Protéines de facteur viii de recombinaison
JP6256882B2 (ja) 2012-02-15 2018-01-10 アムニクス オペレーティング インコーポレイテッド 第ｖｉｉｉ因子組成物、ならびに組成物の作製方法および用途
WO2013120939A1 (fr) 2012-02-15 2013-08-22 Csl Behring Gmbh Variants du facteur de von willebrand ayant une affinité de liaison au facteur viii améliorée
EP2666782A1 (fr) 2012-05-22 2013-11-27 Imnate Sarl Facteur VIII de coagulation avec immunogénicité réduite
WO2013185113A1 (fr) 2012-06-08 2013-12-12 Biogen Idec Ma Inc. Composés pro-coagulants
US10023628B2 (en) 2012-07-06 2018-07-17 Bioverativ Therapeutics Inc. Cell line expressing single chain factor VIII polypeptides and uses thereof
HK1213767A1 (zh) 2012-10-18 2016-07-15 Bioverativ Therapeutics Inc. 使用固定劑量凝血因子的方法
HK1214539A1 (zh) 2012-10-30 2016-07-29 Bioverativ Therapeutics Inc. 應用viii因子多肽的方法
EP4122487A1 (fr) 2013-03-15 2023-01-25 Bioverativ Therapeutics Inc. Formulations de polypeptide de facteur viii
SG10201803999UA (en) * 2013-03-15 2018-06-28 Bayer Healthcare Llc Recombinant factor viii formulations
WO2014144549A1 (fr) 2013-03-15 2014-09-18 Biogen Idec Ma Inc. Préparations contenant un polypeptide du facteur ix
EP2986313B1 (fr) 2013-04-18 2019-06-12 Novo Nordisk A/S Co-agonistes stables de récepteur de glucagon/glp1 à effet prolongé
EP2796145B1 (fr) 2013-04-22 2017-11-01 CSL Ltd. Un complexe covalent de facteur von willebrand et de faktor viii conjugé par un pont disulfure
TW201519900A (zh) * 2013-04-28 2015-06-01 Bayer Healthcare Llc 用於誘導對凝血因子蛋白之免疫耐受性的組成物及方法
US20160311885A1 (en) 2013-08-14 2016-10-27 Biogen Ma Inc. Recombinant factor viii proteins
TW202003554A (zh) 2013-08-14 2020-01-16 美商百歐維拉提夫治療公司 因子ｖｉｉｉ－ｘｔｅｎ融合物及其用途
WO2015035342A2 (fr) 2013-09-08 2015-03-12 Oligasis Llc Conjugués polymère zwittérionique-facteur viii
WO2015059121A1 (fr) * 2013-10-22 2015-04-30 Dbv Technologies Procédé pour traiter l'hémophilie en induisant une tolérance de facteurs sanguins
EP3065769A4 (fr) 2013-11-08 2017-05-31 Biogen MA Inc. Composé de fusion procoagulant
RU2546297C1 (ru) * 2013-11-19 2015-04-10 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт фармакологии" Сибирского отделения Российской академии медицинских наук Средство, улучшающее реологические свойства крови
US10325687B2 (en) 2013-12-06 2019-06-18 Bioverativ Therapeutics Inc. Population pharmacokinetics tools and uses thereof
RU2695428C2 (ru) * 2014-01-20 2019-07-23 Октафарма Аг СПОСОБ ПРОИЗВОДСТВА ФАКТОРА VIII, ИМЕЮЩЕГО УЛУЧШЕННОЕ СООТНОШЕНИЕ FVIII:C/FVIII:Ag
WO2015120056A1 (fr) 2014-02-04 2015-08-13 Biogen Ma Inc. Chromatographie par échange cationique utilisée dans le mode de fixation par écoulement pour enrichir les modifications post-traductionnelles
WO2015132724A1 (fr) * 2014-03-05 2015-09-11 Pfizer Inc. Mutéines améliorées du facteur viii de coagulation
AU2015236340B2 (en) 2014-03-24 2020-02-06 Bioverativ Therapeutics Inc. Lyophilized factor IX formulations
WO2015154090A1 (fr) * 2014-04-04 2015-10-08 Bloodworks Laboratoire ordinaire et analyse hors laboratoire de l'hémostase
US10227559B2 (en) 2014-04-10 2019-03-12 Bayer Healthcare Llc Compounded media powder formulation and method of preparation of liquid medium for cell culture
US10570184B2 (en) 2014-06-04 2020-02-25 Novo Nordisk A/S GLP-1/glucagon receptor co-agonists for medical use
BR112016030950A2 (pt) 2014-07-02 2018-03-27 Csl Ltd polipeptídeo modificado que se liga ao fator viii, complexo, composição farmacêutica, métodos para tratar uma coagulopatia, para produzir um polipeptídeo que compreende um vwf modificado e para aumentar a afinidade de ligação ao fator viii do vwf e a meia-vida do fator viii, uso de um polipeptídeo modificado ou de um complexo, polinucleotídeo, plasmídeo ou vetor, e, célula hospedeira.
MA40864A (fr) 2014-10-31 2017-09-05 Biogen Ma Inc Hypotaurine, gaba, bêta-alanine et choline pour la régulation de l'accumulation de sous-produits résiduaires dans des procédés de culture de cellules mammifères
ES2772933T3 (es) 2015-03-06 2020-07-08 CSL Behring Lengnau AG Factor de von Willebrand modificado que tiene una semivida mejorada
EP3297656B1 (fr) 2015-05-22 2020-01-08 CSL Behring Lengnau AG Polypeptides du facteur von willebrand tronqué pour traiter l'hémophilie
JP6651548B2 (ja) 2015-05-22 2020-02-19 ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト 改変フォン・ヴィルブランド因子を製造するための方法
EA201890423A1 (ru) 2015-08-03 2018-07-31 Биовератив Терапьютикс Инк. Слитые белки фактора ix, способы их получения и применения
US9849125B1 (en) 2015-11-03 2017-12-26 Banner Lifie Sciences LLC Anti-overingestion dosage forms
DK3400002T3 (da) 2016-01-07 2022-04-11 CSL Behring Lengnau AG Muteret, trunkeret von willebrand faktor
RU2018128613A (ru) 2016-01-07 2020-02-07 Цсл Беринг Ленгнау Аг Мутированный фактор фон виллебранда
JP7235511B2 (ja) * 2016-06-24 2023-03-08 モガム・インスティテュート・フォー・バイオメディカル・リサーチ 組換え型一本鎖ｆｖｉｉｉおよびその化学コンジュゲート
SG11201903954WA (en) 2016-11-11 2019-05-30 CSL Behring Lengnau AG Truncated von willebrand factor polypeptides for extravascular administration in the treatment or prophylaxis of a blood coagulation disorder
US11814421B2 (en) 2016-11-11 2023-11-14 CSL Behring Lengnau AG Truncated von Willebrand Factor polypeptides for treating hemophilia
US11104718B2 (en) 2016-11-16 2021-08-31 Bayer Healthcare Llc Red blood cell targeted factor VIII and method of using the same
MX2019006444A (es) 2016-12-02 2019-10-30 Bioverativ Therapeutics Inc Métodos de tratamiento de artropatía hemofílica utilizando factores de coagulación quiméricos.
JP2019536794A (ja) 2016-12-02 2019-12-19 バイオベラティブ セラピューティクス インコーポレイテッド 凝固因子に対する免疫寛容を誘導する方法
EA201991768A1 (ru) 2017-01-31 2020-01-22 Байоверетив Терапьютикс Инк. Слитые белки на основе фактора ix и способы их получения и пути применения
US10335375B2 (en) 2017-05-30 2019-07-02 Patheon Softgels, Inc. Anti-overingestion abuse deterrent compositions
KR20190086269A (ko) * 2018-01-12 2019-07-22 재단법인 목암생명과학연구소 체내 지속형 재조합 당단백질 및 이의 제조방법
PL3793588T3 (pl) 2018-05-18 2025-09-01 Bioverativ Therapeutics Inc. Sposoby leczenia hemofilii a
MX2020012103A (es) 2018-05-18 2021-01-29 Zhengzhou Gensciences Inc Proteina de fusion fviii mejorada y uso de la misma.
CA3157509A1 (fr) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Procedes de traitement d'un trouble oculaire
WO2021091881A1 (fr) * 2019-11-04 2021-05-14 The Trustees Of Columbia University In The City Of New York Compositions de conjugués d'inhibiteurs de caspase de pénétration cellulaire à concentration élevée et procédés associés
AU2020395323A1 (en) * 2019-12-06 2022-06-30 The Children's Hospital Of Philadelphia Compositions and methods for modulating factor VIII function

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59172425A (ja) * 1983-03-18 1984-09-29 Nippon Chemiphar Co Ltd 新規な血液凝固因子誘導体およびその製造法ならびにそれを含有する血液凝固促進剤
US7138505B1 (en) 1984-01-12 2006-11-21 Novartis Vaccines And Diagnostics, Inc. Factor VIII:C nucleic acid molecules
US4970300A (en) * 1985-02-01 1990-11-13 New York University Modified factor VIII
US5451521A (en) 1986-05-29 1995-09-19 Genetics Institute, Inc. Procoagulant proteins
US5422260A (en) 1986-05-29 1995-06-06 Genetics Institute, Inc. -Legal Affairs Human factor VIII:c muteins
EP0294910B1 (fr) 1987-06-12 1996-09-11 Immuno Ag Protéines à activité de facteur VIII, procédé pour leur production utilisant des cellules modifiées par génie génétique et compositions pharmaceutiques les contenant
IL86693A (en) 1987-06-12 1994-06-24 Stichting Centraal Lab Proteins with factor VIII activity, process for their preparation using genetically engineered cells and pharmaceutical compositions containing them
US6346513B1 (en) 1987-06-12 2002-02-12 Baxter Trading Gmbh Proteins with factor VIII activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
AU2473388A (en) * 1987-11-16 1989-06-22 Scripps Clinic And Research Foundation Treatment of factor viii inhibitors
US5166322A (en) 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
SE465222C5 (sv) 1989-12-15 1998-02-10 Pharmacia & Upjohn Ab Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning
US5766897A (en) 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
US6376463B1 (en) 1992-04-07 2002-04-23 Emory University Modified factor VIII
US6037452A (en) 1992-04-10 2000-03-14 Alpha Therapeutic Corporation Poly(alkylene oxide)-Factor VIII or Factor IX conjugate
CA2124690C (fr) 1992-10-02 2007-09-11 Thomas Osterberg Composition contenant une preparation du facteur de coagulation viii, methode de preparation et utilisation d'un surfactant comme stabilisateur
WO1994015625A1 (fr) * 1993-01-15 1994-07-21 Enzon, Inc. Conjugues de polymere et de facteur viii
SE504074C2 (sv) 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
JPH09504174A (ja) 1993-10-29 1997-04-28 インサイト ファーマシューティカルズ，インク． プロテアーゼネキシン１変異体を含むキメラ蛋白
IL113010A (en) 1994-03-31 1999-10-28 Pharmacia & Upjohn Ab Pharmaceutical formulation comprising factor viii with an activity of at least 500iu/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration
BE1008491A3 (fr) * 1994-07-14 1996-05-07 Croix Rouge De Belgique Depart Sequence polypeptidique antigenique du facteur viii, fragments et/ou epitopes de celle-ci.
CA2204726A1 (fr) 1994-11-09 1996-12-27 Robin E. Offord Polymeres fonctionnalises destines a une ligation dirigee
WO1997001197A1 (fr) * 1995-06-21 1997-01-09 Motorola Inc. Procede et antenne produisant un diagramme de rayonnement omnidirectionnel
AU6486196A (en) 1995-07-11 1997-02-10 Chiron Corporation Novel factor viii:c polypeptide analogs with altered protease sites
SE9503380D0 (sv) * 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
AT403438B (de) 1996-05-24 1998-02-25 Immuno Ag Pharmazeutische präparation mit faktor viii prokoagulationsaktivität und vwf-bindungsaktivität
US6458563B1 (en) * 1996-06-26 2002-10-01 Emory University Modified factor VIII
EP0964702B1 (fr) * 1996-08-02 2006-10-04 Ortho-McNeil Pharmaceutical, Inc. Polypeptides possedant un polymere soluble dans l'eau a n-terminal lie par covalence simple
CA2225189C (fr) 1997-03-06 2010-05-25 Queen's University At Kingston Gene et proteine du facteur viii du chien et methodes d'utilisation
ES2297889T3 (es) 1997-07-14 2008-05-01 Bolder Biotechnology, Inc. Derivados de hormona de crecimiento y proteinas relacionadas.
US6753165B1 (en) * 1999-01-14 2004-06-22 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
CN1113656C (zh) * 1997-10-17 2003-07-09 丰收技术股份有限公司 从富含血小板的血浆中沉淀富集生长因子的纤维蛋白原浓缩物
EP0922446A1 (fr) 1997-12-03 1999-06-16 Applied Research Systems Ars Holding N.V. Préparation des conjugués du GRF-PEG par un méthode en solution spécifique à un site
US6593294B1 (en) 1998-04-27 2003-07-15 Opperbas Holding B.V. Pharmaceutical composition comprising Factor VIII and neutral liposomes
US6759216B1 (en) 1998-11-06 2004-07-06 Emory University Glycosylated, low antigenicity low immunogenicity factor VIII
EP1129186B2 (fr) 1998-11-10 2016-11-30 Stichting Sanquin Bloedvoorziening Polypeptide du facteur viii avec activite de facteur viii:c
US6136599A (en) 1998-12-10 2000-10-24 Bayer Corporation Human hybrid host cell for mammalian gene expression
US6358703B1 (en) 1998-12-10 2002-03-19 Bayer Corporation Expression system for factor VIII
CA2359345A1 (fr) 1999-01-14 2000-07-20 Bolder Biotechnology, Inc. Techniques permettant de produire des proteines contenant des residus cysteine libres
AU5282200A (en) 1999-05-24 2000-12-12 American National Red Cross, The Methods of reducing factor viii clearance and compositions therefor
CA2739933A1 (fr) * 2000-02-11 2001-08-16 Bayer Healthcare Llc Molecules de type facteur vii ou viia
PL206105B1 (pl) 2000-09-19 2010-07-30 Emory Universityemory University Zmodyfikowany ludzki czynnik VIII oraz sposób modyfikacji ludzkiego czynnika VIII ze zmniejszeniem reaktywności na przeciwciało hamujące i zachowaniem aktywności prokoagulacyjnej
JP2005518181A (ja) 2001-01-12 2005-06-23 ジ・アメリカン・ナショナル・レッド・クロス 第ｖｉｉｉ因子のヘパラン硫酸プロテオグリカン仲介性クリアランスを低下させるための方法および組成物
CZ20032454A3 (en) * 2001-03-22 2004-03-17 Novo Nordisk Health Care Ag Coagulation factor vii derivative
WO2002098454A2 (fr) 2001-05-31 2002-12-12 D. Collen Research Foundation Vzw Onderwijsen Navorsing Campus Gasthuisberg K.U. Leuven Molecules recombinees a immunogenicite reduite, procedes et produits intermediaires pour les obtenir et leur utilisation dans des compositions pharmaceutiques et des outils diagnostiques
WO2002096454A1 (fr) 2001-05-31 2002-12-05 D. Collen Research Foundation Vzw Molecules recombinees avec immunogenicite reduite, procedes et intermediaires permettant d'obtenir ces molecules, et utilisation de ces molecules dans des compositions pharmaceutiques et des outils diagnostiques
ES2331909T3 (es) 2001-06-14 2010-01-20 The Scripps Research Institute Factor viii estabilizado con enlaces disulfuro modificados geneticamente.
ES2319745T3 (es) 2001-10-05 2009-05-12 Expression Therapeutics, Llc Secuencias de acidos nucleicos y aminoacidos que codifican polipeptidos de factor viii de alto nivel de expresion, y metodos de uso.
WO2003087161A1 (fr) 2002-04-18 2003-10-23 Merck Patent Gmbh Facteur viii modifie
US8003117B2 (en) 2002-11-20 2011-08-23 Nof Corporation Polyalkylene glycol derivative and modified bio-related substance
JP4412461B2 (ja) 2002-11-20 2010-02-10 日油株式会社 修飾された生体関連物質、その製造方法および中間体
MXPA05007151A (es) 2002-12-31 2005-09-21 Nektar Therapeutics Al Corp Polimeros terminados en maleimida hidroliticamente estables.
JP4490369B2 (ja) 2002-12-31 2010-06-23 ネクター セラピューティクス アラバマ，コーポレイション マレアミド酸ポリマー誘導体及びこれらの生物学的複合体
KR101207247B1 (ko) 2003-01-06 2012-12-03 넥타르 테라퓨틱스 티올-선택성 수용성 중합체 유도체
BRPI0407882B1 (pt) * 2003-02-26 2021-07-27 Nektar Therapeutics Composição compreendendo conjugados de polímero-porção de fator viii e seu método de fabricação
US20040180054A1 (en) * 2003-03-13 2004-09-16 Hanmi Pharm. Co., Ltd. Physiologically active polypeptide conjugate having prolonged in vivo half-life
US20050176108A1 (en) * 2003-03-13 2005-08-11 Young-Min Kim Physiologically active polypeptide conjugate having prolonged in vivo half-life
CN1820024B (zh) * 2003-05-12 2011-06-22 阿费麦克斯公司 新的聚(乙二醇)修饰的化合物及其用途
EP2644206B1 (fr) 2003-05-23 2019-04-03 Nektar Therapeutics Derives du PEG qui contiennent deux chaînes de PEG
EP1502921A1 (fr) 2003-07-29 2005-02-02 ZLB Behring GmbH Mutants du Facteur VIII (FVIII) humain recombinants ayant une meilleure stabilité
US20050123997A1 (en) 2003-10-30 2005-06-09 Lollar John S. Modified fVIII having reduced immunogenicity through mutagenesis of A2 and C2 epitopes
US7211559B2 (en) 2003-10-31 2007-05-01 University Of Maryland, Baltimore Factor VIII compositions and methods
CA2547569C (fr) 2003-12-03 2013-04-16 University Of Rochester Facteur viii recombine presentant une activite specifique amelioree
WO2006027111A1 (fr) 2004-09-06 2006-03-16 Zlb Behring Gmbh Facteur viii de coagulation modifie presentant une meilleure stabilite
PT2363414T (pt) 2004-11-12 2022-08-04 Bayer Healthcare Llc Modificação de fviii direcionada a sítio
EP1871801A2 (fr) 2005-04-01 2008-01-02 Novo Nordisk Health Care AG Analogues du fviii de coagulation sanguine
AU2007245190B2 (en) 2006-03-31 2011-07-21 Takeda Pharmaceutical Company Limited Pegylated factor VIII
US7645860B2 (en) 2006-03-31 2010-01-12 Baxter Healthcare S.A. Factor VIII polymer conjugates

Also Published As

Publication number Publication date
HUE050542T2 (hu) 2020-12-28
AU2005304622B2 (en) 2012-03-29
ES2930143T3 (es) 2022-12-07
RU2007121517A (ru) 2008-12-20
CN101124331A (zh) 2008-02-13
RU2423380C2 (ru) 2011-07-10
PT3130601T (pt) 2020-10-01
PH12014500352A1 (en) 2015-07-20
MX2007005466A (es) 2007-10-19
CN103214569A (zh) 2013-07-24
NO20200044A1 (no) 2007-06-27
LT2363414T (lt) 2022-10-25
NO20072997L (no) 2007-06-27
IL182903A (en) 2014-09-30
EP2371856A2 (fr) 2011-10-05
HN2007015683A (es) 2011-07-11
JP6109523B2 (ja) 2017-04-05
HRP20070268B1 (hr) 2018-04-20
US20060115876A1 (en) 2006-06-01
MA29663B1 (fr) 2008-08-01
FR19C1031I1 (fr) 2019-06-28
NZ555032A (en) 2010-02-26
US20160051633A1 (en) 2016-02-25
EP3130601B1 (fr) 2020-07-15
JP2017105773A (ja) 2017-06-15
FR19C1031I2 (fr) 2020-06-05
EP1824988B1 (fr) 2017-04-19
JP6559642B2 (ja) 2019-08-14
CN105753968A (zh) 2016-07-13
EP3323829B1 (fr) 2020-07-15
JP2008524117A (ja) 2008-07-10
KR20120136413A (ko) 2012-12-18
CY1119292T1 (el) 2018-02-14
KR20130036780A (ko) 2013-04-12
PH12014500352B1 (en) 2019-09-25
PL1824988T3 (pl) 2018-01-31
HK1117875A1 (en) 2009-01-23
HK1218718A1 (zh) 2017-03-10
CN105148287B (zh) 2019-07-09
BE2019C523I2 (fr) 2025-02-10
NO344606B1 (no) 2020-02-10
AU2005304622A1 (en) 2006-05-18
EP1824988A4 (fr) 2008-12-31
DK2371856T3 (en) 2022-08-08
JP2015134780A (ja) 2015-07-27
CN103214569B (zh) 2016-12-28
CY2019024I1 (el) 2019-11-27
HRP20180481B1 (hr) 2022-02-18
JP6487895B2 (ja) 2019-03-20
KR20070110260A (ko) 2007-11-16
KR101243564B1 (ko) 2013-03-27
EP3323829A1 (fr) 2018-05-23
EP2371856A3 (fr) 2012-03-14
BRPI0517795B1 (pt) 2020-03-31
CN103102406B (zh) 2015-05-27
EP2363414A3 (fr) 2012-03-21
NL300989I1 (nl) 2019-05-22
DK2363414T3 (da) 2022-08-08
WO2006053299A2 (fr) 2006-05-18
US20100081615A1 (en) 2010-04-01
CA2586379C (fr) 2012-04-03
KR101904630B1 (ko) 2018-10-04
LTC1824988I2 (lt) 2021-02-25
NL300989I2 (nl) 2019-11-28
LT1824988T (lt) 2017-10-25
KR101468345B1 (ko) 2014-12-03
IL232540A (en) 2017-08-31
BRPI0517795A (pt) 2008-10-21
PL2371856T3 (pl) 2022-08-22
SI3130601T1 (sl) 2020-11-30
US9096656B2 (en) 2015-08-04
BR122016022033B8 (pt) 2021-05-25
CN101124331B (zh) 2013-04-24
KR20160105928A (ko) 2016-09-07
EP2363414A2 (fr) 2011-09-07
CY2019024I2 (el) 2019-11-27
LT2371856T (lt) 2022-08-25
HRP20180481A2 (hr) 2018-06-29
KR20180110192A (ko) 2018-10-08
EP2772500A1 (fr) 2014-09-03
HUE059193T2 (hu) 2022-10-28
SI1824988T1 (sl) 2017-11-30
LUC00118I2 (fr) 2019-12-27
BR122016022033B1 (pt) 2021-03-02
HUE033776T2 (en) 2018-01-29
PT2371856T (pt) 2022-08-12
EP3243834A1 (fr) 2017-11-15
ES2633916T3 (es) 2017-09-26
IL232540A0 (en) 2014-06-30
IL182903A0 (en) 2007-08-19
IL234433B (en) 2019-11-28
DK1824988T3 (en) 2017-08-07
MX392760B (es) 2025-03-24
PH12019501613A1 (en) 2020-09-14
LT3130601T (lt) 2020-09-10
EP2772500B1 (fr) 2019-12-25
KR20140019489A (ko) 2014-02-14
ES2930159T3 (es) 2022-12-07
JP2013067621A (ja) 2013-04-18
CA2586379A1 (fr) 2006-05-18
US7632921B2 (en) 2009-12-15
CN105148287A (zh) 2015-12-16
UA95225C2 (ru) 2011-07-25
BRPI0517795A8 (pt) 2018-12-26
WO2006053299A3 (fr) 2006-08-24
EP3243833A1 (fr) 2017-11-15
US9364520B2 (en) 2016-06-14
KR101483917B1 (ko) 2015-01-16
HRP20070268A2 (en) 2007-09-30
SI2371856T1 (sl) 2022-09-30
ES2821832T3 (es) 2021-04-27
EP3243833B1 (fr) 2020-06-17
KR101654011B1 (ko) 2016-09-05
PL2363414T3 (pl) 2022-09-05
EP2363414B1 (fr) 2022-05-18
CN103102406A (zh) 2013-05-15
LTPA2019509I1 (lt) 2019-08-26
HUE060016T2 (hu) 2023-01-28
KR20140091618A (ko) 2014-07-21
PT1824988T (pt) 2017-07-21
JP2017101028A (ja) 2017-06-08
BRPI0517795B8 (pt) 2021-05-25
JP6018238B2 (ja) 2016-11-02
CY1123384T1 (el) 2021-12-31
NO20210454A1 (no) 2007-06-27
SI2363414T1 (sl) 2022-09-30
EP2371856B1 (fr) 2022-05-18
EP1824988A2 (fr) 2007-08-29
MX350293B (es) 2017-09-04
NO345800B1 (no) 2021-08-09
US20130274445A1 (en) 2013-10-17
LUC00118I1 (fr) 2019-05-13
HK1182121A1 (en) 2013-11-22
HUS1900026I1 (hu) 2022-04-28
EP3153181A1 (fr) 2017-04-12
CN107082806A (zh) 2017-08-22
PT2363414T (pt) 2022-08-04
EP3130601A1 (fr) 2017-02-15

Similar Documents

Publication Publication Date Title
IL234433B (en) Site-directed modification of factor viii
ZA200705293B (en) Improved osteotome
IL183634A0 (en) Polymer-von willebrand factor-conjugates
EP1802588A4 (fr) Amino-pyrimidones substitues et utilisation de ceux-ci
EP1785131A4 (fr) Preparation externe de type s/o
ZA200606315B (en) Novel amido-substituted hydroxy-6-phenylphenanthridines
GB0415789D0 (en) Novel combination
AU300055S (en) Scrubber
PL1720633T3 (pl) Płuczka wieżowa gazu
GB0428026D0 (en) Infant aid
GB0517332D0 (en) Improved building components
GB2416051B (en) Selection of component
ZA200508325B (en) Manufacture of kerbstones
GB0421155D0 (en) Piece of mind plan
GB0415217D0 (en) Compounds and uses thereof
GB0412872D0 (en) Novel structures
PL369353A1 (pl) Zestaw elementów budowlanych
AU157294S (en) External cornice corner member
TWM275831U (en) Improved structure of cinerary urn
SI1835938T1 (sl) Konjugati polimera in von Willebrandovega faktorja
GB0414968D0 (en) Novel preparation
GB0415721D0 (en) Novel preparation
GB0402464D0 (en) Child walker